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(S)-2-Methylbutanoyl chloride (2). 1H NMR (500 MHz, CDCl3): H 0.95 (3H, t, J = 7.5 Hz, 
H4), 1.26 (3H, d, J = 7.5 Hz, H5), 1.59 (1H, m, H3a), 1.80 (1H, m, H3b), 2.80 (1H, q, J = 7.0 
Hz, H2); 13C NMR (125 MHz, CDCl3): C 11.3 (C4), 16.7 (C5), 26.7 (C3), 53.1 (C2), 177.8 
(C1). 
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Figure 1: 1H NMR spectrum of 2 (500 MHz, CDCl3) 
 
Figure 2: 13C NMR spectrum of 2 (125 MHz, CDCl3) 
  
S5 
 
(S)-2-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one (4). 1H NMR (500 MHz, CD3OD): H 
0.88 (3H, t, J = 7.5 Hz, H4'), 1.11 (3H, d, J = 6.5 Hz, H5'), 1.33 (1H, m, H3'a), 1.78 (1H, m, 
H3'b), 3.84 (1H, m, H2'), 5.81 (2H, s, H3, H5); 13C NMR (125 MHz, CD3OD): C 12.4 (C4'), 
17.2 (C5'), 28.2 (C3'), 46.7 (C2'), 96.0 (C3, C5), 105.3 (1), 165.8 (C2, C4, C6), 211.4 (C1'). 
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Figure 3: 1H NMR spectrum of 4 (500 MHz, CD3OD) 
 
Figure 4: 13C NMR spectrum of 4 (125 MHz, CD3OD) 
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(S)-1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-methylbutan-1-one (5). 
1H NMR (500 MHz, CDCl3): H 0.23 (2 × 3H, s, H1'', H2''), 0.32 (2 × 3H, s, H1''', H2'''), 0.88 
(3H, t, J = 7.5 Hz, H4'), 0.97 (3 × 3H, s, H4'', H5'', H6''), 0.99 (3 × 3H, s, H4''', H5''', H6'''), 1.12 
(3H, d, J = 6.5Hz, H5'), 1.43 (1H, m, H3'a), 1.78 (1H, m, H3'b), 3.82 (1H, m, H2'), 5.85 (1H, 
d, J = 2.0 Hz, H3), 6.04 (1H, d, J = 2.0 Hz, H5), 13.43 (1H, s, OH6); 13C NMR (125 MHz, 
CDCl3): C -4.2 (C1'', C2''), -3.7 (C1''', C2'''), 11.0 (C4'), 16.9 (C5'), 18.1 (C3''), 18.9 (C3'''), 
25.5 (C4'', C5'', C6''), 26.1 (C4''', C5''', C6'''), 26.5 (C3'), 45.0 (C2'),  102.0 (C3), 103.1 (C5), 
108.4 (C1), 158.8 (C4), 161.7 (C2), 166.5 (C6), 210.5 (C1'). 
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Figure 5: 1H NMR spectrum of 5 (500 MHz, CDCl3) 
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(S,E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxy-phenyl)-2-methylbutan-
1-one (olympicin A) (6). 1H NMR (500 MHz, CDCl3): H 0.88 (3H, t, J = 7.5 Hz, H4'), 1.12 
(3H, d, J = 6.5 Hz, H5'), 1.36 (1H, m, H3'a), 1.61 (3H, s, H9"), 1.69 (3H, s, H8"), 1.74 (3H, s, 
H10"), 1.79 m (1H, m, H3'), 2.10 (2H, m, H5"), 2.13 (2H, m, H4"), 3.68 (1H, m, H2'), 4.56 
(2H, d, J = 6.5 Hz, H1"), 5.10 (1H, m, H6"), 5.44 (1H, br s, HO4), 5.50 (1H, m, H2"), 5.91 
(1H, d, J = 2.0 Hz, H3), 5.98 (1H, d, J = 2.0 Hz, H5), 14.10 (1H, s, HO6); 13C NMR (125 MHz, 
CDCl3): C 11.9 (C4'), 16.5 (C5'), 16.6 (C10"), 17.7 (C9"), 25.7 (C8"), 26.2 (C5"), 26.9 (C3'), 
39.5 (C4"), 46.2 (C2'), 65.6 (C1"), 91.5 (C3), 96.5 (C5), 105.9 (C1), 118.2 (C2"), 122.6 (C6"), 
132.0 (C7"), 142.4 (C3"), 161.9 (C4), 162.6 (C2), 167.5 (C6), 210.4 (C1').  
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Figure 6: 1H NMR spectrum of 6 (500 MHz, CDCl3) 
 
Figure 7: 13C NMR spectrum of 6 (125 MHz, CDCl3) 
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(S)-1-(2,4-Dihydroxy-6-((3-methylbut-2-en-1-yl)oxy)phenyl)-2-methylbutan-1-one (7). 1H 
NMR (500 MHz, CDCl3): H 0.88 (3H, t, J = 7.5 Hz, H4'), 1.13 (3H, d, J = 6.5 Hz, H5'), 1.33 
(1H, m, H3'a), 1.76 (3H, s, H5"), 1.78 (1H, m, H3'), 1.82 (3H, s, H4"), 3.66 (1H, m, H2'), 4.55 
(2H, d, J = 6.5 Hz, H1"), 5.51 (1H, t, J = 6.5 Hz, H2"), 5.70 (1H, br s, HO4), 5.93 (1H, d, J = 
2.0 Hz, H3), 6.00 (1H, d, J = 2.0 Hz, H5), 14.07 (1H, br s, HO6); 13C NMR (125 MHz, CDCl3): 
C 12.0 (C4'), 16.7 (C5'), 18.4 (C5"), 25.9 (C4"), 27.1, (C3'), 46.3 (C2'), 65.8 (C1"), 91.7 (C3), 
96.7 (C4), 106.1 (C1), 118.6 (C2"), 139.3 (C3"), 162.3 (C4), 162.8 (C2), 167.7 (C5), 210.6 
(C1'). 
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Figure 8: 1H NMR spectrum of 7 (500 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: 13C NMR spectrum of 7 (125 MHz, CDCl3) 
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(S)-1-(2,4-Dihydroxy-6-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy)phenyl)-
2-methylbutan-1-one (8). 1H NMR (500 MHz, CDCl3): H 0.90 (3H, t, J = 7.5 Hz, H4'), 1.13 
(3H, d, J = 6.5 Hz, H5'), 1.37 (1H, m, H3'), 1.61 (3H, s, H13"), 1.62 (3H, s, H14"), 1.69 (3H, 
s, H12"), 1.75 (3H, s, H15"), 1.80 (1H, m, H3'), 1.99 (2H, s, H8"), 2.07 (2H, s, H9"),  2.11 (2H, 
m, H5"), 2.13 (2H,  m, H4"), 3.67 (1H, m, H2'), 4.57 (2H, d, J = 6.5 Hz, H1"), 5.08 (1H, m, 
H10"),  5.12 (1H, m, H6"), 5.52 (1H, m, H2"), 5.93 (1H, d, J = 2.5 Hz, H3), 5.99 (1H, d, J = 
2.5 Hz, H5), 14.05 (1H, s, HO6); 13C NMR (125 MHz, CDCl3): C 12.1 (C4'), 16.2 (C13"), 
16.8 (C5'), 16.9 (C15"), 17.9 (C14"), 25.9 (C12"), 26.5 (C5"), 26.9 (C9"), 27.0 (C3'), 39.7 
(C4"), 39.9 (C8"), 46.3 (C2'), 65.9 (C1"), 91.8 (C3), 96.7 (C5), 106.1 (C1), 118.4 (C2"), 123.7 
(C6"), 124.5 (C10"), 131.6 (C11"), 135.9 (C7"), 142.7 (C3"), 162.3 (C4), 162.8 (C2), 167.7 
(C6), 210.6 (C1'). 
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Figure 10: 1H NMR spectrum of 8 (500 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
Figure 11: 13C NMR spectrum of 8 (125 MHz, CDCl3) 
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(2S)-1-(2-((3,7-Dimethyloctyl)oxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (9). 1H 
NMR (CDCl3): H 0.88 (3H, t, J = 7.5 Hz, H4'), 0.89 (6H, d, J = 6.5 Hz, H8" and H9"), 0.97 
(3H, d, J = 6.5 Hz, H10"), 1.15 (3H, d, J = 6.5 Hz, H5'), 1.18 (2H, m, H6"), 1.19 (1H, m, H2"a), 
1.35 (3H, m, H3'a, H5"), 1.43 (1H, m, H2"b), 1.54 (1H, m, H7"), 1.66 (3H, m, H3", H4"a), 
1.82 (1H, m, H3'b), 1.89 (1H, m, H4"b), 3.72 (1H, m, H2'), 4.04 (2H, d, J = 6.5 Hz, H1"), 5.36 
(1H, br s, HO4), 5.93 (1H, d, J = 2.0 Hz, H3), 5.99 (1H, d, J = 2.0 Hz, H5), 14.05 (1H, s, HO6); 
13C NMR (CDCl3): C 11.7 (C4'), 16.8 (C5'), 19.6 (C10"), 22.6 (C8" and C9"), 24.6 (C5"), 26.6 
(C3'), 28.0 (C7"), 29.9 (C3"), 36.0 (C4"), 37.5 (C2"), 39.2 (C6"), 46.0 (C2'), 66.7 (C1"), 91.5 
(C3), 96.5 (C5), 105.8 (C1), 162.4 (C4), 162.8 (C2), 167.4 (C6), 210.4 (C1'). 
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Figure 12: 1H NMR spectrum of 9 (500 MHz, CDCl3) 
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(S)-1-(2,4-Dihydroxy-6-(isopentyloxy)phenyl)-2-methylbutan-1-one (10). 1H NMR (500 
MHz, CDCl3): H 0.89 (3H, t, J = 7.5 Hz, H4'), 0.98 (6H, d, J = 6.5 Hz, H4" and H5"), 1.14 
(3H, d, J = 6.5 Hz, H5'), 1.41 (1H, m, H3'a), 1.73 (2H, m, H2"), 1.80 (1H, m, H3"), 1.81 (1H, 
m, H3'b), 3.69 (1H, m, H2'), 4.02 (2H, d, J = 6.5 Hz, H1"), 5.40 (1H, br s, HO4),  5.92 (1H, d, 
J = 2.0 Hz, H3), 5.99 (1H, d, J = 2.0 Hz, H5), 14.17 (1H, s, HO6); 13C NMR (125 MHz, CDCl3): 
C 11.7 (C4'), 16.8 (C5'), 22.5 (C4" and C5"), 25.2 (C3"), 26.6 (C3'), 37.7 (C2"), 46.0 (C2'), 
67.5 (C1"), 91.5 (C3), 96.5 (C5), 105.8 (C1), 162.4 (C4), 162.8 (C2), 167.4 (C6), 210.4 (C1'). 
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Figure 13: 1H NMR spectrum of 10 (500 MHz, CDCl3) 
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(S)-1-(2-(Benzyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (11). 1H NMR (500 
MHz, CDCl3): H 0.68 (3H, t, J = 6.5 Hz, H4'), 1.00 (3H, d, J = 6.5 Hz, H5'), 1.29 (1H, m, H3'), 
1.71 (1H, m, H3'), 3.57 (1H, m, H2'), 5.08 (2H, s, H1"), 6.00 (1H, d, J = 2.0 Hz, H3), 6.01 (1H, 
d, J = 2.0 Hz, H5), 7.38-7.42 (5H, m, H3"-7"), 14.00 (1H, s, HO6); 13C NMR (125 MHz, 
CDCl3): C 11.7 (C4'), 16.8 (C5'), 26.9 (C3'), 46.2 (C2'), 71.6 (C1"), 92.0 (C5),  97.1 (C3),  
106.1 (C1), 128.4 (C3" and C7"), 128.8 (C5"), 129.0 (C4" and C6"), 135.6 (C2"), 162.2 (C4), 
162.5 (C6), 167.8 (C2), 210.6 (C1'). 
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Figure 14: 1H NMR spectrum of 11 (500 MHz, CDCl3) 
 
Figure 15: 13C NMR spectrum of 11 (125 MHz, CDCl3) 
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(S)-1-(2,4-Dihydroxy-6-(octyloxy)phenyl)-2-methylbutan-1-one (12). 1H NMR (500 MHz, 
CDCl3): H 0.89 (3H, t, J = 7.5 Hz,  H8"), 0.90 (3H, t, J = 7.5 Hz, H4'), 1.16 (3H, d, J = 7.0 
Hz, H5'), 1.26-1.40 (8H,  m, H3"-H6"), 1.38 (1H, m, H3'), 1.46 (2H, m, H2"), 1.81 m (1H, m, 
H3'), 1.85 (2H, m, H7"), 3.72 (1H, q, J = 6.5 Hz, H2'), 4.00 (2H, t, J = 6.5 Hz, H1"), 5.42 (1H, 
br s, HO4), 5.91 (1H, d, J = 2.0 Hz, H3), 5.99 (1H, d, J = 2.0 Hz, H5), 14.06 (1H, s, HO6); 13C 
NMR (125 MHz, CDCl3): C 12.0 (C4'), 14.3 (C8"), 17.1 (C5'), 22.8 (C7"), 26.5 (C3'), 26.9, 
29.3, 29.4, 29.5, 32.0 (C2"-C6"), 46.3 (C2'), 69.4 (C1"), 91.5 (C3), 96.8 (C5), 106.2 (C1), 162.2 
(C4), 163.0 (C2), 167.8 (C6), 210.5 (C1'). 
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Figure 16: 1H NMR spectrum of 12 (500 MHz, CDCl3) 
 
Figure 17: 13C NMR spectrum of 12 (125 MHz, CDCl3) 
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(S)-1-(2-(Decyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (13). 1H NMR (500 MHz, 
CDCl3): H 0.88 (3H, t, J = 7.5 Hz, H4'), 0.89 (3H, t, J = 7.5 Hz,  H10"), 1.17 (3H, d, J = 6.5 
Hz, H5'), 1.28-1.31 (12H,  m, H3"-8"), 1.34 (1H, m, H3'), 1.46 (2H, m, H2"), 1.81 (1H, m, 
H3'), 1.84 (2H, m, H9"), 3.72 (1H, q, J = 6.5 Hz, H2'), 4.00 (2H, t, J = 6.5 Hz, H1"), 5.92 (1H, 
d, J = 2.0 Hz, H3), 6.00 (1H, d, J = 2.0 Hz, H5), 14.16 (1H, s, HO6); 13C NMR (125 MHz, 
CDCl3): C 12.0 (C4'), 14.3 (C10"), 17.3 (C5'), 26.5, 26.6, 29.1, 29.4, 29.5, 29.6, 29.8, 29.9, 
32.0 (C2"-C9"), 46.3 (C2'), 69.3 (C1"), 91.6 (C3), 96.8 (C5), 106.2 (C1), 162.3 (C4), 163.0 
(C2), 167.7 (C6), 210.6 (C1'). 
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Figure 18: 1H NMR spectrum of 13 (500 MHz, CDCl3) 
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(S)-1-(2-(Dodecyloxy)-4,6-dihydroxyphenyl)-2-methylbutan-1-one (14). 1H NMR (500 
MHz, CDCl3): H 0.88 (3H, t, J = 7.5 Hz, H4'), 0.89 (3H, t, J = 7.5 Hz,  H12"), 1.16 (3H, d, J 
= 6.5 Hz, H5'), 1.28-1.30 (16H, m, H3"-10"), 1.35 (1H, m, H3'), 1.46 (2H, m, H2"), 1.83 m 
(1H, m, H3'), 1.86 (2H,  m, H11"), 3.73 (1H, q, J = 6.5 Hz, H2'), 4.00 (2H, t, J = 6.5 Hz, H1"), 
5.92 (1H, d, J = 2.0 Hz, H3), 6.00 (1H, d, J = 2.0 Hz, H5), 6.02 (1H, br s, HO4), 14.19 (1H, s, 
HO6);  13C NMR (125 MHz, CDCl3): C 12.0 (C4'), 14.3 (C12"), 17.1 (C5'), 22.9 (C2"), 26.9 
(C3'), 26.5, 29.3, 29.5, 29.6, 29.77 (2C), 29.8, 29.9, 32.1 (C3"-C11"), 46.3 (C2'), 69.4 (C1"), 
91.7 (C3), 96.8 (C5), 106.1 (C1), 162.5 (C4), 163.0 (C2), 167.7 (C6), 210.7 (C1'). 
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Figure 19: 1H NMR spectrum of 14 (500 MHz, CDCl3) 
 
Figure 20: 13C NMR spectrum of 14 (125 MHz, CDCl3) 
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(S)-1-(2,4-Dihydroxy-6-(octadecyloxy)phenyl)-2-methylbutan-1-one (15). 1H NMR (500 
MHz, CDCl3): H 0.89 (3H, t, J = 7.5 Hz, H4'), 0.91 (3H, t, J = 7.5 Hz,  H18"), 1.16 (3H, d, J 
= 6.5 Hz, H5'), 1.27-1.33 (28H, m, H3"-16"), 1.42 (1H, m, H3'), 1.46 (2H, m, H2"), 1.81 (1H, 
m, H3'), 1.85 (2H,  m, H17"), 3.73 (1H, q, J = 6.5 Hz, H2'), 4.00 (2H, t, J = 6.5 Hz, H1"), 5.92 
(1H, d, J = 2.0 Hz, H3), 6.00 (1H, d, J = 2.0 Hz, H5), 6.07 (1H, br s, HO4), 14.12 (1H, s, HO6);  
13C NMR (125 MHz, CDCl3): C 12.0 (C4'), 14.3 (C18"), 17.1 (C5'), 22.9 (C3"), 26.5 (C3'), 
26.9, 29.3, 29.6, 29.8-29.9 (C4"-C17"), 32.2 (C2"), 46.3 (C2'), 69.4 (C1"), 91.6 (C3), 96.8 (C5), 
106.1 (C1), 162.3 (C4), 163.0 (C2), 167.8 (C6), 210.6 (C1'). 
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Figure 21: 1H NMR spectrum of 15 (500 MHz, CDCl3) 
 
Figure 22: 13C NMR spectrum of 15 (125 MHz, CDCl3) 
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(E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)ethanone (18). 1H 
NMR (500 MHz, (CD3)2CO): H 1.59 (3H, s, H10"), 1.64 (3H, s, H9"), 1.77 (3H, s, H8"), 2.11-
2.16 (4H, m, H4", H5"), 2.55 (3H, s, H2'),  4.64 (2H, d, J = 6.5 Hz, H1"), 5.11 (1H, m, H6"), 
5.56 (1H, m, H2"), 5.93 (1H, d, J = 2.0 Hz, H3), 6.03 (1H, d, J = 2.0 Hz, H5), 13.91 (1H, s, 
HO6); 13C NMR (125 MHz, (CD3)2CO): C 16.7 (C10"), 17.8 (C9"), 25.9 (C8"), 27.0 (C5"), 
33.2 (C2'), 40.1 (C4"), 66.4 (C1"), 92.8 (C3), 96.6 (C5), 106.1 (C1), 119.9 (C2"), 124.7 (C6"), 
132.2 (C7"), 142.6 (C3"), 164.0 (C4), 166.0 (C2), 168.3 (C6), 203.5 (C1'). 
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Figure 23: 1H NMR spectrum of 18 (500 MHz, (CD3)2CO) 
 
Figure 24: 13C NMR spectrum of 18 (125 MHz, (CD3)2CO) 
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(E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)propan-1-one (19). 
1H NMR (500 MHz, CDCl3): H 1.15 (3H, t, J = 7.0 Hz, H3'), 1.61 (3H, s, H9"), 1.68 (3H, s, 
H8"), 1.74 (3H, s, H10"), 2.10 (2H, m, H5"), 2.13 (2H, m, H4"), 3.03 (2H, q, J = 7.0 Hz, H-2'), 
4.57 (2H, d, J = 6.5 Hz, H1"), 5.10 (1H, m, H6"), 5.51 (1H, m, H2"), 5.53 (1H, s, HO4), 5.91 
(1H, d, J = 2.0 Hz, H3), 5.98 (1H, d, J = 2.0 Hz, H5), 14.05 (1H, s, HO6); 13C NMR (125 MHz, 
CDCl3): C 9.0 (C3'),  16.9 (C10"), 18.0 (C9"),  25.9 (C8"), 26.5 (C5"), 37.8 (C2'), 39.7 (C4"), 
66.0 (C1"), 91.7 (C3), 96.6 (C5), 106.3 (C1), 118.6 (C2"), 123.8 (C6"), 132.3 (C7"), 142.4 
(C3"), 162.4 (C4), 163.2 (C2), 167.4 (C6), 207.0 (C1'). 
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Figure 25: 1H NMR spectrum of 19 (500 MHz, CDCl3) 
                                  
Figure 26: 13C NMR spectrum of 19 (125 MHz, CDCl3) 
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(E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)butan-1-one (20). 1H 
NMR (500 MHz, CDCl3): H 0.97 (3H, t, J = 6.5 Hz, H4'), 1.61 (3H, s, H9"), 1.69 (3H, s, H8"), 
1.71 (2H, s, H3'), 1.74 (3H, s, H10"),  2.10 (2H, m, H5"), 2.13 (2H, m, H4"), 2.97 (2H, t, J = 
7.0 Hz, H-2'), 4.54 (2H, d, J = 6.5 Hz, H1"), 5.10 (1H, m, H6"), 5.50 (1H, t, J = 6.5Hz, H2"), 
5.91 (1H, s, HO4), 5.93 (1H, d, J = 2.0 Hz, H3), 5.99 (1H, d, J = 2.0 Hz, H5), 14.10 (1H, s, 
HO6); 13C NMR (125 MHz, CDCl3): C 14.2 (C4'), 16.9 (C10"), 17.9 (C9"), 18.9 (C2'), 25.9 
(C8"), 26.5 (C5"), 39.7 (C4"), 46.5 (C3'), 65.9 (C1"), 92.1 (C3), 96.6 (C5), 106.0 (C1), 118.4 
(C2"), 123.8 (C6"), 132.2 (C7"), 142.7 (C3"), 162.3 (C4), 163.4 (C2), 167.3 (C6), 206.9 (C1').  
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Figure 27: 1H NMR spectrum of 20 (500 MHz, CDCl3) 
 
Figure 28: 13C NMR spectrum of 20 (125 MHz, CDCl3) 
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(E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)pentan-1-one (21). 
1H NMR (500 MHz, CDCl3): H 0.92 (3H, t, J = 6.5 Hz, H5'), 1.37 (2H, q, J = 6.5 Hz, H4'), 
1.61 (3H, s, H9"), 1.64 (2H, m H3'), 1.69 (3H, s, H8"), 1.74 (3H, s, H10"), 2.10 (2H, m, H5"), 
2.13 (2H, m, H4"), 3.00 (2H, m, H-2'), 4.55 (2H, d, J = 6.5 Hz, H1"), 5.10 (1H, t, J = 6.5 Hz, 
H6"), 5.50 (1H, t, J = 6.5 Hz, H2"), 5.92 (1H, d, J = 2.0 Hz, H3), 5.99 (1H, d, J = 2.0 Hz, H5), 
6.38 (1H, s, HO4),14.04 (1H, s, HO6); 13C NMR (125 MHz, CDCl3): C 14.2(C5'),  16.9 
(C10"), 17.9 (C9"), 22.8 (C4'), 25.9 (C8"), 26.5 (C5"), 27.4 (C3'), 39.6 (C4"), 44.4 (C2'), 65.9 
(C1"), 91.9 (C3), 96.6 (C5), 106.1 (C1), 118.4 (C2"), 123.8 (C6"), 132.2 (C7"), 142.6 (C3"), 
162.9 (C4), 163.1 (C2), 167.4 (C6), 206.8 (C1'). 
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Figure 29: 1H NMR spectrum of 21 (500 MHz, CDCl3) 
 
Figure 30: 13C NMR spectrum of 21 (125 MHz, CDCl3) 
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 (E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)decan-1-one (22). 
1H NMR (400 MHz, CDCl3): H 0.88 (3H, t, J = 6.5 Hz, H10'), 1.26 (12H, br s, H3'-H9'), 1.35 
(2H, m, H3'), 1.61 (3H, s, H9"), 1.68 (3H, s, H8"), 1.74 (3H, s, H10"), 2.09 (2H, m, H5"), 2.13 
(2H, m, H4"), 2.99 (2H, t, J = 7.6 Hz, H-2'), 4.56 (2H, d, J = 6.4 Hz, H1"), 5.11 (1H, t, J = 6.8 
Hz, H6"), 5.51 (1H, t, J = 6.8 Hz, H2"), 5.92 (1H, d, J = 2.4 Hz, H3), 5.99 (1H, d, J = 2.4 Hz, 
H5), 14.10 (1H, s, HO6); 13C NMR (125 MHz, CDCl3): C 14.4 (C10'), 16.9 (C10"), 17.9 (C9"), 
22.9 (C9'), 25.4 (C3'), 25.9 (C8"), 26.6 (C5"), 29.6 (C4'), 29.7-29.8 (C5'-C7'), 32.2 (C8'), 39.8 
(C4"), 44.7 (C2'), 65.9 (C1"), 91.9 (C3), 96.6 (C5), 106.1 (C1), 118.5 (C2"), 123.8 (C6"), 132.2 
(C7"), 142.5 (C3"), 163.0 (C4), 163.1 (C2), 167.5 (C6), 206.5 (C1').  
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Figure 31: 1H NMR spectrum of 22 (500 MHz, CDCl3) 
 
Figure 32: 13C NMR spectrum of 22 (125 MHz, CDCl3) 
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(E)-1-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)octadecan-1-one 
(23). 1H NMR (400 MHz, CDCl3): H 0.89 (3H, t, J = 6.8Hz, H18'), 1.26-1.35 (34H, br s, H3'-
H17'), 1.62 (3H, s, H9"), 1.69 (3H, s, H8"), 1.75 (3H, s, H10"), 2.10 (2H, m, H5"), 2.13 (2H, 
m, H4"), 2.99 (2H, m, H-2'), 4.55 (2H, d, J = 6.5 Hz, H1"), 5.10 (1H, t, J = 6.5 Hz, H6"), 5.50 
(1H, t, J = 6.5 Hz, H2"), 5.91 (1H, d, J = 2.0 Hz, H3), 5.98 (1H, d, J = 2.0 Hz, H5), 14.12 (1H, 
s, HO6); 13C NMR (100 MHz, CDCl3): C 14.3 (C10'), 16.9 (C10"), 17.9 (C9"), 22.9 (C9'), 
25.3 (C3'), 25.9 (C8"), 26.5 (C5"), 29.6 (C4'), 29.8-29.9 (C5'-C17'), 32.1 (C8'), 39.7 (C4"), 44.7 
(C2'), 65.9 (C1"), 91.7 (C3), 96.6 (C5), 106.3 (C1), 118.5 (C2"), 123.8 (C6"), 132.2 (C7"), 
142.5 (C3"), 162.6 (C4), 163.1 (C2), 167.5 (C6), 206.7 (C1').  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S41 
 
Figure 33: 1H NMR spectrum of 23 (500 MHz, CDCl3) 
 
Figure 34: 13C NMR spectrum of 23 (125 MHz, CDCl3) 
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(E)-(2-((3,7-Dimethylocta-2,6-dien-1-yl)oxy)-4,6-dihydroxyphenyl)(phenyl)-methanone 
(24). 1H NMR (500 MHz, CDCl3): H 1.52 (3H, s, H9"), 1.61 (3H, s, H8"), 1.71 (3H, s, H10"), 
1.85 (2H, m, H4"), 1.94 (2H, m, H5"), 4.21 (2H, d, J = 6.5 Hz, H1"), 4.61 (1H, t, J = 6.5 Hz, 
H2"), 5.05 (1H, m, H6"), 5.89 (1H, d, J = 2.0 Hz, H3), 6.07 (1H, d, J = 2.0 Hz, H5), 7.36 (2H, 
dt, J = 8.0, 1.5 Hz, H4' and H6'), 7.42 (1H, d, J = 8.0 Hz, H5'), 7.49 (2H, dt, J = 8.0, 1.5 Hz, 
H3' and H7'), 12.27 (1H, s, HO6); 13C NMR (125 MHz, CDCl3): C 16.8 (C10"), 17.9 (C9"), 
25.9 (C8"), 26.4 (C5"), 39.4 (C4"), 65.5 (C1"), 92.4 (C3), 96.5 (C5), 106.1 (C1), 118.1 (C2"), 
124.0 (C6"), 127.6 (C4', 6'), 127.8 (C3', C7'), 130.7 (C5'), 132.0 (C7"), 140.7 (C3"), 142.5 
(C2'), 162.4 (C2), 163.5 (C4), 165.9 (C6), 200.1 (C1'). 
  
S43 
 
Figure 35: 1H NMR spectrum of 24 (500 MHz, CDCl3) 
 
 
Figure 36: 13C NMR spectrum of 24 (125 MHz, CDCl3) 
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General procedure for the Friedel-Crafts acylation of phloroglucinol. A solution of 
phloroglucinol (3; 5.00 g, 39.7 mmol) in carbon disulphide (50 mL) was transferred into a two-
necked round-bottomed flask and allowed to stir while aluminium trichloride (21.68 g, 162.7 
mmol, 4.1 equiv) was added. Nitrobenzene (20 mL) was then added to the solution over 30 
min. The solution was heated under reflux at 55 °C for 30 min. A solution of acyl chloride 
(39.7 mmol, 1.0 equiv) dissolved in 5 mL nitrobenzene was added to the reaction mixture over 
30 min, followed by heating for another 30 min. The reaction mixture was allowed to cool with 
stirring and then poured into an ice-water bath (200 mL). 50 mL of 3 M hydrochloric acid was 
then added and the mixture extracted with diethyl ether (3 × 250 mL). The organic solvents 
were removed under reduced pressure. The oily residue containing the acylphloroglucinol (16) 
was subjected to VLC over SiGel PF254 using hexane and EtOAc of increasing polarity. The 
target acylphloroglucinols typically eluted with 20-45% EtOAc in hexane and were isolated in 
yields between 50% and 60% (see Table S1 for the actual yields of each acylphloroglucinol 
16b-16g). 
General procedure for the TBDMS protection of acylphloroglucinols. Acylphloroglucinol 
16 (ca. 20.0 mmol) was dissolved in dry acetone (typically 10 mL, but up to 70 mL may be 
required) and transferred into a suitably-sized round bottom flask. Imidazole (3 equiv) was 
added to the solution and the reaction mixture stirred for 5 min, followed by the addition of 
TBDMS-Cl (2.1 equiv). The reaction mixture was stirred for 2 h at room temperature. Acetone 
was removed from the reaction mixture under reduced pressure and the residue taken up in 
chloroform and washed with 1 M HCl (150 mL). The organic layer was dried using anhydrous 
magnesium sulphate, filtered and the solvent was removed under reduced pressure. The crude 
product purified by VLC over silica gel using hexane and EtOAc of increasing polarity. The 
target TBDMS-protected acylphloroglucinols typically eluted with 3-10% EtOAc in hexane 
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and were isolated in yields between 40% and 85% (see Table S1 for the actual yields of each 
acylphloroglucinol 17a-17g). 
General procedure for the simultaneous O-geranylation and deprotection of TBDMS-
protected acylphloroglucinols. TBDMS-protected acylphloroglucinol 17 (ca. 2 mmol) was 
dissolved in dry DMF (10 mL) and anhydrous potassium carbonate (1.5 equiv) was added. The 
mixture was stirred for approximately 5 min followed by the addition of geranyl bromide (1.2 
equiv). The mixture was heated at 80 °C for 3 h with stirring. The reaction mixture was poured 
over water and extracted with chloroform. The solvent in the organic layer was removed under 
reduced pressure. The crude product was purified by chromatography over silica gel by VLC.  
The target geranylated acylphloroglucinols typically eluted with 4-20% EtOAc in hexane and 
were isolated in yields between 5% and 45% (see Table S1 for the actual yields of each 
geranylated acylphloroglucinol 18-24). 
 
Table S1. Yields of the individual Friedel-Crafts acylation, TBDMS protection and 
geranylation steps in the synthesis of 18-24.  
Acylation of 
phloroglucinol (3) 
TBDMS protection of 
acylphloroglucinol 16 
Geranylation and 
deprotection of 17 
Acyl group 
Compound Yield (%) Compound Yield (%) Compound Yield (%) 
16aa n/a 17a 40 18 11 acetyl 
16b 60 17b 68 19 6.4 propanoyl 
16c 56 17c 73 20 14 butanoyl 
16d 55 17d 46 21 22 pentanoyl 
16e 51 17e 82 22 10 decanoyl 
16f 60 17f 69 23 46 octadecanoyl 
16g 54 17g 58 24 32 benzoyl 
aAcetylphloroglucinol 16a is commercially available  
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1-(2,4,6-Trihydroxyphenyl)propan-1-one (16b). 1H NMR (400 MHz, (CD3)2CO): H 1.10 
(3H, t, J = 7.2 Hz, H3'), 3.08 (2H, q, J = 7.2 Hz, H2'), 5.92 (2 × 1H, s, H3 and H5), 10.88 (3 × 
1H, br s, HO2, HO4 and HO6). 
 
Figure 37: 1H NMR spectrum of 16b (400 MHz, (CD3)2CO) 
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1-(2,4,6-Trihydroxyphenyl)butan-1-one (16c). 1H NMR (400 MHz, (CD3)2CO): H 0.91 (3H, 
t, J = 7.2 Hz, H4'), 1.65 (2H, m, H3'), 3.00 (2H, t, J = 7.2 Hz, H2'), 5.88 (2 × 1H, s, H3 and 
H5), 11.14 (3 × 1H, br s, HO2, HO4 and HO6). 
 
Figure 38: 1H NMR spectrum of 16c (400 MHz, (CD3)2CO) 
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1-(2,4,6-Trihydroxyphenyl)pentan-1-one (16d). 1H NMR (400 MHz, (CD3)2CO): H 0.91 
(3H, t, J = 7.2 Hz, H5'), 1.37 (2H, m, H4'),  1.63 (2H, m, H3'),  3.06 (2H, t, J = 7.2 Hz, H2'), 
5.92 (2 × 1H, s, H3 and H5), 11.78 (3 × 1H, br s, OH2, OH4 and OH6). 
 
Figure 39: 1H NMR spectrum of 16d (400 MHz, (CD3)2CO) 
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1-(2,4,6-Trihydroxyphenyl)decan-1-one (16e). 1H NMR (400 MHz, (CD3)2CO): H 0.88 (3H, 
t, J = 7.2 Hz, 10'), 1.30 (6 × 2H, m, H4'-9'), 1.67 (2H, m, H3'),  3.07 (2H, t, J = 7.2 Hz, H2'), 
5.92 (2 × 1H, s, H3 and H5), 11.71 (3 × 1H, br s, OH2, OH4 and OH6). 
 
Figure 40: 1H NMR spectrum of 16e (400 MHz, (CD3)2CO) 
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1-(2,4,6-Trihydroxyphenyl)octadecan-1-one (16f). 1H NMR (400 MHz, (CD3)2CO): H 0.88 
(3H, t, J = 7.2 Hz, 18'), 1.29 (14 × 2H, m, H4'-17'), 1.67 (2H, m, H3'),  3.07 (2H, t, J = 7.2 Hz, 
H2'), 5.93 (2 × 1H, s, H3 and H5), 11.64 (3 × 1H, br s, OH2, OH4 and OH6). 
 
Figure 41: 1H NMR spectrum of 16f (400 MHz, (CD3)2CO) 
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1-(2,4,6-Trihydroxyphenyl)phen-1-one (16g). 1H NMR (400 MHz, (CD3)2CO): H 5.98 (2 × 
1H, s, H3 and H5), 7.40 (2 × 1H, d, J = 8.0 Hz, H4', H6'), 7.47 (1H, t, J = 8.0 Hz, H5'), 7.61 (2 
× 1H, d, J = 8.0 Hz, H3' and H7'), 10.17 (3 × 1H, br s, HO2, HO4 and HO6). 
 
Figure 42: 1H NMR spectrum of 16g (400 MHz, (CD3)2CO) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-ethan-1-one (17a). 1H NMR 
(400 MHz, CDCl3): H 0.24 (2 × 3H, s, H1'', H2''), 0.35 (2 × 3H, s, H1''', H2'''), 0.97 (3 x 3H, s, 
H4'', H5'', H6''), 1.01 (3 × 3H, s, H4''', H5''', H6'''), 2.63 (3H, s, H2'), 5.85 (1H, d, J = 2.0 Hz), 
H3, 6.03 (1H, d, J = 2.0 Hz, H5), 13.50 (1H, s, OH6).  
 
Figure 43: 1H NMR spectrum of 17a (400 MHz, CDCl3) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-propan-1-one (17b). 1H 
NMR (400 MHz, CDCl3): H 0.23 (2 × 3H, s, H1'', H2''), 0.35 (2 × 3H, s, H1''', H2'''), 0.97 (3H, 
t, J = 7.2 Hz, H3'), 1.14 (3 × 3H, s, H4'', H5'', H6''), 1.41 (3 × 3H, s, H4''', H5''', H6'''), 1.78 (1H, 
m, H2'b), 3.83 (1H, m, H2'a), 5.83 (1H, d, J = 2.0 Hz, H3), 6.04 (1H, d, J = 2.0 Hz, H5), 13.42 
(1H, s, OH6).  
 
Figure 44: 1H NMR spectrum of 17b (400 MHz, CDCl3) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-butan-1-one (17c). 1H NMR 
(400 MHz, CDCl3): H 0.22 (2 × 3H, s, H1'', H2''), 0.34 (2 × 3H, s, H1''', H2'''), 0.95 (3H, t, J = 
6.8Hz, H4'), 0.96 (3 × 3H, s, H4'', H5'', H6''), 1.01 (3 × 3H, s, H4''', H5''', H6'''), 1.70 (2H, m, 
H3'), 3.03 (2H, t, J = 6.0Hz, H2'), 5.84 (1H, d, J = 2.0 Hz, H3), 6.02 (1H, d, J = 2.0 Hz, H5), 
13.52 (1H, s, OH6).  
 
Figure 45: 1H NMR spectrum of 17c (400 MHz, CDCl3) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-decan-1-one (17e). 1H NMR 
(400 MHz, CDCl3): H 0.23 (2 × 3H, s, H1'', H2''), 0.35 (2 × 3H, s, H1''', H2'''), 0.91 (3H, t, J = 
7.2 Hz, H10'), 0.97 (3 × 3H, s, H4'', H5'', H6''), 1.02 (3 × 3H, s, H4''', H5''', H6'''), 1.27-1.33 (br 
s, 6 × 2H, H3'-H9'), 3.05 (2H, J = 7.2 Hz, H2'), 5.85 (1H, d, J = 2.0 Hz, H3), 6.04 (1H, d, J = 
2.0 Hz, H5), 13.54 (1H, s, OH6).  
 
Figure 46: 1H NMR spectrum of 17e (400 MHz, CDCl3) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-octadecan-1-one (17f). 1H 
NMR (400 MHz, CDCl3): H 0.23 (2 × 3H, s, H1'', H2''), 0.35 (2 × 3H, s, H1''', H2'''), 0.89 (3H, 
t, J = 7.2 Hz, H18'), 0.98 (3 × 3H, s, H4'', H5'', H6''), 1.02 (3 × 3H, s, H4''', H5''', H6), 1.27 (br 
s, 13 × 2H, H3'-H17'), 3.05 (2H, J = 7.2 Hz, H2'), 5.85 (1H, d, J = 2.0 Hz, H3), 6.04 (1H, d, J 
= 2.0 Hz, H5), 13.52 (1H, s, OH6).  
 
Figure 47: 1H NMR spectrum of 17f (400 MHz, CDCl3) 
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1-(2,4-bis((tert-Butyldimethylsilyl)oxy)-6-hydroxyphenyl)-2-phen-1-one (17g). 1H NMR 
(500 MHz, CDCl3): H 0.10 (2 × 3H, s, H1'', H2''), 0.27 (2 × 3H, s, H1''', H2'''), 0.62 (3 × 3H, 
s, H4'', H5'', H6''), 1.00 (3 × 3H, s, H4''', H5''', H6'''), 5.87 (1H, d, J = 2.5 Hz, H3), 6.16 (1H, d, 
J = 2.5 Hz, H5), 7.40 (2H, dd, J = 10.0, 2.5 Hz, H4',6'), 7.47 (1H, dt, J = 10.0, 2.5 Hz, H5'), 
7.68 (2H, dd, J = 10.0, 2.5 Hz, H3', H7'), 11.17 (1H, s, OH6). 
 
Figure 48: 1H NMR spectrum of 17g (400 MHz, CDCl3) 
 
 
